de Lemos Mário L, Guenter Jolene, Kletas Victoria
1 Provincial Pharmacy, Systemic Therapy Program, BC Cancer Agency, Vancouver, BC, Canada.
2 Pharmacy, Systemic Therapy Program, BC Cancer Agency, Vancouver, BC, Canada.
J Oncol Pharm Pract. 2018 Dec;24(8):634-636. doi: 10.1177/1078155217718384. Epub 2017 Jul 16.
High-dose loperamide is often used for the acute management of chemotherapy-induced diarrhea, with a maximum daily dosing of up to 24 mg. Recently, the US Food and Drug Administration has issued a warning that loperamide can cause rare serious cardiac events, including QT prolongation, torsades de pointes, cardiac arrest and death. Most events were reported in patients taking very high doses for an extended period of time. Daily intake ranged from 64 mg to 1600 mg, often continuously for weeks or months. In addition, the reported serum levels of loperamide ranged from 22 ng/mL to 210 ng/mL, which is likely significantly higher than that expected from patients taking the recommended doses for chemotherapy-induced diarrhea. Overall, the incidence of serious cardiac events associated with loperamide remains low. In balance, the risk of uncontrolled complications from chemotherapy-induced diarrhea is likely greater than the rare cardiac risk associated with the chronic misuse of much higher doses of loperamide.
高剂量洛哌丁胺常用于化疗引起腹泻的急性处理,最大日剂量可达24毫克。最近,美国食品药品监督管理局发布警告称,洛哌丁胺可导致罕见的严重心脏事件,包括QT间期延长、尖端扭转型室性心动过速、心脏骤停和死亡。大多数事件报告于长期服用极高剂量的患者中。每日摄入量为64毫克至1600毫克,通常持续数周或数月。此外,报告的洛哌丁胺血清水平为22纳克/毫升至210纳克/毫升,这可能显著高于服用推荐剂量治疗化疗引起腹泻的患者预期的水平。总体而言,与洛哌丁胺相关的严重心脏事件发生率仍然较低。权衡之下,化疗引起腹泻导致的失控并发症风险可能大于长期滥用高得多剂量洛哌丁胺所带来的罕见心脏风险。